Global Oligonucleotide-based Therapy Medicinal Product Market Growth (Status and Outlook) 2026-2032
The global Oligonucleotide-based Therapy Medicinal Product market size is predicted to grow from US$ 13040 million in 2025 to US$ 16910 million in 2032; it is expected to grow at a CAGR of 3.8% from 2026 to 2032.
Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing.
The Oligonucleotide Drug Delivery Market is driven by the rapid advancement in oligonucleotide-based therapies, including antisense, siRNA, and aptamer-based drugs, which hold immense potential for treating various genetic and rare diseases. These therapies rely on oligonucleotides to modulate gene expression, inhibit specific targets, or diagnose genetic disorders. As the understanding of genetic mechanisms and precision medicine continues to evolve, the demand for efficient and targeted delivery systems for oligonucleotide drugs grows. Innovations in drug delivery technologies, such as lipid nanoparticles and conjugates, as well as the expansion of oligonucleotide drug pipelines, further contribute to market expansion. However, a significant challenge for this market is the need to address the complexity of drug delivery, including overcoming biological barriers, minimizing off-target effects, and ensuring long-term safety and efficacy. Overcoming delivery hurdles, optimizing pharmacokinetics, and navigating regulatory pathways are ongoing challenges. Additionally, the market faces competition from traditional drug therapies, and the need for continuous research and development to enhance the delivery efficiency and patient acceptance of oligonucleotide drugs. Striking a balance between providing efficient and precise oligonucleotide drug delivery solutions while addressing safety and regulatory considerations is crucial for the continued growth of the Oligonucleotide Drug Delivery Market.
LPI (LP Information)' newest research report, the “Oligonucleotide-based Therapy Medicinal Product Industry Forecast” looks at past sales and reviews total world Oligonucleotide-based Therapy Medicinal Product sales in 2025, providing a comprehensive analysis by region and market sector of projected Oligonucleotide-based Therapy Medicinal Product sales for 2026 through 2032. With Oligonucleotide-based Therapy Medicinal Product sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oligonucleotide-based Therapy Medicinal Product industry.
This Insight Report provides a comprehensive analysis of the global Oligonucleotide-based Therapy Medicinal Product landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oligonucleotide-based Therapy Medicinal Product portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oligonucleotide-based Therapy Medicinal Product market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oligonucleotide-based Therapy Medicinal Product and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oligonucleotide-based Therapy Medicinal Product.
This report presents a comprehensive overview, market shares, and growth opportunities of Oligonucleotide-based Therapy Medicinal Product market by product type, application, key players and key regions and countries.
Segmentation by Type:
Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing.
The Oligonucleotide Drug Delivery Market is driven by the rapid advancement in oligonucleotide-based therapies, including antisense, siRNA, and aptamer-based drugs, which hold immense potential for treating various genetic and rare diseases. These therapies rely on oligonucleotides to modulate gene expression, inhibit specific targets, or diagnose genetic disorders. As the understanding of genetic mechanisms and precision medicine continues to evolve, the demand for efficient and targeted delivery systems for oligonucleotide drugs grows. Innovations in drug delivery technologies, such as lipid nanoparticles and conjugates, as well as the expansion of oligonucleotide drug pipelines, further contribute to market expansion. However, a significant challenge for this market is the need to address the complexity of drug delivery, including overcoming biological barriers, minimizing off-target effects, and ensuring long-term safety and efficacy. Overcoming delivery hurdles, optimizing pharmacokinetics, and navigating regulatory pathways are ongoing challenges. Additionally, the market faces competition from traditional drug therapies, and the need for continuous research and development to enhance the delivery efficiency and patient acceptance of oligonucleotide drugs. Striking a balance between providing efficient and precise oligonucleotide drug delivery solutions while addressing safety and regulatory considerations is crucial for the continued growth of the Oligonucleotide Drug Delivery Market.
LPI (LP Information)' newest research report, the “Oligonucleotide-based Therapy Medicinal Product Industry Forecast” looks at past sales and reviews total world Oligonucleotide-based Therapy Medicinal Product sales in 2025, providing a comprehensive analysis by region and market sector of projected Oligonucleotide-based Therapy Medicinal Product sales for 2026 through 2032. With Oligonucleotide-based Therapy Medicinal Product sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oligonucleotide-based Therapy Medicinal Product industry.
This Insight Report provides a comprehensive analysis of the global Oligonucleotide-based Therapy Medicinal Product landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oligonucleotide-based Therapy Medicinal Product portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oligonucleotide-based Therapy Medicinal Product market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oligonucleotide-based Therapy Medicinal Product and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oligonucleotide-based Therapy Medicinal Product.
This report presents a comprehensive overview, market shares, and growth opportunities of Oligonucleotide-based Therapy Medicinal Product market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Antisense Oligonucleotides (ASO)
- siRNA
- mRNA
- Neuromuscular Diseases
- hATTR
- COVID-19
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sarepta Therapeutics
- Ionis Pharmaceuticals
- Alnylam
- Biogen
- Nippon Shinyaku
- Sobi
- Novartis
- BioNTech
- Pfizer
- Moderna Therapeutics
- Jazz Pharmaceuticals
- CureVac
- Regulus Therapeutics
- ProQR
- Secarna
- MiNA Therapeutics
- Sylentis
- Arrowhead
- Silence Therapeutics
- Dicerna
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oligonucleotide-based Therapy Medicinal Product Market Size (2021-2032)
2.1.2 Oligonucleotide-based Therapy Medicinal Product Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Oligonucleotide-based Therapy Medicinal Product by Country/Region (2021, 2025 & 2032)
2.2 Oligonucleotide-based Therapy Medicinal Product Segment by Type
2.2.1 Antisense Oligonucleotides (ASO)
2.2.2 siRNA
2.2.3 mRNA
2.2.4 Oligonucleotide-based Therapy Medicinal Product Market Size by Type
2.2.4.1 Oligonucleotide-based Therapy Medicinal Product Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Type (2021-2026)
2.3 Oligonucleotide-based Therapy Medicinal Product Segment by Application
2.3.1 Neuromuscular Diseases
2.3.2 hATTR
2.3.3 COVID-19
2.3.4 Other
2.3.5 Oligonucleotide-based Therapy Medicinal Product Market Size by Application
2.3.5.1 Oligonucleotide-based Therapy Medicinal Product Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.5.2 Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Application (2021-2026)
3 OLIGONUCLEOTIDE-BASED THERAPY MEDICINAL PRODUCT MARKET SIZE BY PLAYER
3.1 Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Player
3.1.1 Global Oligonucleotide-based Therapy Medicinal Product Revenue by Player (2021-2026)
3.1.2 Global Oligonucleotide-based Therapy Medicinal Product Revenue Market Share by Player (2021-2026)
3.2 Global Oligonucleotide-based Therapy Medicinal Product Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 OLIGONUCLEOTIDE-BASED THERAPY MEDICINAL PRODUCT BY REGION
4.1 Oligonucleotide-based Therapy Medicinal Product Market Size by Region (2021-2026)
4.2 Global Oligonucleotide-based Therapy Medicinal Product Annual Revenue by Country/Region (2021-2026)
4.3 Americas Oligonucleotide-based Therapy Medicinal Product Market Size Growth (2021-2026)
4.4 APAC Oligonucleotide-based Therapy Medicinal Product Market Size Growth (2021-2026)
4.5 Europe Oligonucleotide-based Therapy Medicinal Product Market Size Growth (2021-2026)
4.6 Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Oligonucleotide-based Therapy Medicinal Product Market Size by Country (2021-2026)
5.2 Americas Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026)
5.3 Americas Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oligonucleotide-based Therapy Medicinal Product Market Size by Region (2021-2026)
6.2 APAC Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026)
6.3 APAC Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Oligonucleotide-based Therapy Medicinal Product Market Size by Country (2021-2026)
7.2 Europe Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026)
7.3 Europe Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oligonucleotide-based Therapy Medicinal Product by Region (2021-2026)
8.2 Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026)
8.3 Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL OLIGONUCLEOTIDE-BASED THERAPY MEDICINAL PRODUCT MARKET FORECAST
10.1 Global Oligonucleotide-based Therapy Medicinal Product Forecast by Region (2027-2032)
10.1.1 Global Oligonucleotide-based Therapy Medicinal Product Forecast by Region (2027-2032)
10.1.2 Americas Oligonucleotide-based Therapy Medicinal Product Forecast
10.1.3 APAC Oligonucleotide-based Therapy Medicinal Product Forecast
10.1.4 Europe Oligonucleotide-based Therapy Medicinal Product Forecast
10.1.5 Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Forecast
10.2 Americas Oligonucleotide-based Therapy Medicinal Product Forecast by Country (2027-2032)
10.2.1 United States Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.2.2 Canada Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.2.3 Mexico Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.2.4 Brazil Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.3 APAC Oligonucleotide-based Therapy Medicinal Product Forecast by Region (2027-2032)
10.3.1 China Oligonucleotide-based Therapy Medicinal Product Market Forecast
10.3.2 Japan Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.3.3 Korea Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.3.4 Southeast Asia Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.3.5 India Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.3.6 Australia Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.4 Europe Oligonucleotide-based Therapy Medicinal Product Forecast by Country (2027-2032)
10.4.1 Germany Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.4.2 France Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.4.3 UK Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.4.4 Italy Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.4.5 Russia Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.5 Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Forecast by Region (2027-2032)
10.5.1 Egypt Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.5.2 South Africa Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.5.3 Israel Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.5.4 Turkey Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.6 Global Oligonucleotide-based Therapy Medicinal Product Forecast by Type (2027-2032)
10.7 Global Oligonucleotide-based Therapy Medicinal Product Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Oligonucleotide-based Therapy Medicinal Product Forecast
11 KEY PLAYERS ANALYSIS
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Information
11.1.2 Sarepta Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
11.1.3 Sarepta Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Sarepta Therapeutics Main Business Overview
11.1.5 Sarepta Therapeutics Latest Developments
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Information
11.2.2 Ionis Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Product Offered
11.2.3 Ionis Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Ionis Pharmaceuticals Main Business Overview
11.2.5 Ionis Pharmaceuticals Latest Developments
11.3 Alnylam
11.3.1 Alnylam Company Information
11.3.2 Alnylam Oligonucleotide-based Therapy Medicinal Product Product Offered
11.3.3 Alnylam Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Alnylam Main Business Overview
11.3.5 Alnylam Latest Developments
11.4 Biogen
11.4.1 Biogen Company Information
11.4.2 Biogen Oligonucleotide-based Therapy Medicinal Product Product Offered
11.4.3 Biogen Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Biogen Main Business Overview
11.4.5 Biogen Latest Developments
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Information
11.5.2 Nippon Shinyaku Oligonucleotide-based Therapy Medicinal Product Product Offered
11.5.3 Nippon Shinyaku Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Nippon Shinyaku Main Business Overview
11.5.5 Nippon Shinyaku Latest Developments
11.6 Sobi
11.6.1 Sobi Company Information
11.6.2 Sobi Oligonucleotide-based Therapy Medicinal Product Product Offered
11.6.3 Sobi Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sobi Main Business Overview
11.6.5 Sobi Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Oligonucleotide-based Therapy Medicinal Product Product Offered
11.7.3 Novartis Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 BioNTech
11.8.1 BioNTech Company Information
11.8.2 BioNTech Oligonucleotide-based Therapy Medicinal Product Product Offered
11.8.3 BioNTech Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 BioNTech Main Business Overview
11.8.5 BioNTech Latest Developments
11.9 Pfizer
11.9.1 Pfizer Company Information
11.9.2 Pfizer Oligonucleotide-based Therapy Medicinal Product Product Offered
11.9.3 Pfizer Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Pfizer Main Business Overview
11.9.5 Pfizer Latest Developments
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Information
11.10.2 Moderna Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
11.10.3 Moderna Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Moderna Therapeutics Main Business Overview
11.10.5 Moderna Therapeutics Latest Developments
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Information
11.11.2 Jazz Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Product Offered
11.11.3 Jazz Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Jazz Pharmaceuticals Main Business Overview
11.11.5 Jazz Pharmaceuticals Latest Developments
11.12 CureVac
11.12.1 CureVac Company Information
11.12.2 CureVac Oligonucleotide-based Therapy Medicinal Product Product Offered
11.12.3 CureVac Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 CureVac Main Business Overview
11.12.5 CureVac Latest Developments
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Information
11.13.2 Regulus Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
11.13.3 Regulus Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Regulus Therapeutics Main Business Overview
11.13.5 Regulus Therapeutics Latest Developments
11.14 ProQR
11.14.1 ProQR Company Information
11.14.2 ProQR Oligonucleotide-based Therapy Medicinal Product Product Offered
11.14.3 ProQR Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 ProQR Main Business Overview
11.14.5 ProQR Latest Developments
11.15 Secarna
11.15.1 Secarna Company Information
11.15.2 Secarna Oligonucleotide-based Therapy Medicinal Product Product Offered
11.15.3 Secarna Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Secarna Main Business Overview
11.15.5 Secarna Latest Developments
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Information
11.16.2 MiNA Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
11.16.3 MiNA Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 MiNA Therapeutics Main Business Overview
11.16.5 MiNA Therapeutics Latest Developments
11.17 Sylentis
11.17.1 Sylentis Company Information
11.17.2 Sylentis Oligonucleotide-based Therapy Medicinal Product Product Offered
11.17.3 Sylentis Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Sylentis Main Business Overview
11.17.5 Sylentis Latest Developments
11.18 Arrowhead
11.18.1 Arrowhead Company Information
11.18.2 Arrowhead Oligonucleotide-based Therapy Medicinal Product Product Offered
11.18.3 Arrowhead Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Arrowhead Main Business Overview
11.18.5 Arrowhead Latest Developments
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Information
11.19.2 Silence Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
11.19.3 Silence Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Silence Therapeutics Main Business Overview
11.19.5 Silence Therapeutics Latest Developments
11.20 Dicerna
11.20.1 Dicerna Company Information
11.20.2 Dicerna Oligonucleotide-based Therapy Medicinal Product Product Offered
11.20.3 Dicerna Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Dicerna Main Business Overview
11.20.5 Dicerna Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oligonucleotide-based Therapy Medicinal Product Market Size (2021-2032)
2.1.2 Oligonucleotide-based Therapy Medicinal Product Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Oligonucleotide-based Therapy Medicinal Product by Country/Region (2021, 2025 & 2032)
2.2 Oligonucleotide-based Therapy Medicinal Product Segment by Type
2.2.1 Antisense Oligonucleotides (ASO)
2.2.2 siRNA
2.2.3 mRNA
2.2.4 Oligonucleotide-based Therapy Medicinal Product Market Size by Type
2.2.4.1 Oligonucleotide-based Therapy Medicinal Product Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Type (2021-2026)
2.3 Oligonucleotide-based Therapy Medicinal Product Segment by Application
2.3.1 Neuromuscular Diseases
2.3.2 hATTR
2.3.3 COVID-19
2.3.4 Other
2.3.5 Oligonucleotide-based Therapy Medicinal Product Market Size by Application
2.3.5.1 Oligonucleotide-based Therapy Medicinal Product Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.5.2 Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Application (2021-2026)
3 OLIGONUCLEOTIDE-BASED THERAPY MEDICINAL PRODUCT MARKET SIZE BY PLAYER
3.1 Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Player
3.1.1 Global Oligonucleotide-based Therapy Medicinal Product Revenue by Player (2021-2026)
3.1.2 Global Oligonucleotide-based Therapy Medicinal Product Revenue Market Share by Player (2021-2026)
3.2 Global Oligonucleotide-based Therapy Medicinal Product Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 OLIGONUCLEOTIDE-BASED THERAPY MEDICINAL PRODUCT BY REGION
4.1 Oligonucleotide-based Therapy Medicinal Product Market Size by Region (2021-2026)
4.2 Global Oligonucleotide-based Therapy Medicinal Product Annual Revenue by Country/Region (2021-2026)
4.3 Americas Oligonucleotide-based Therapy Medicinal Product Market Size Growth (2021-2026)
4.4 APAC Oligonucleotide-based Therapy Medicinal Product Market Size Growth (2021-2026)
4.5 Europe Oligonucleotide-based Therapy Medicinal Product Market Size Growth (2021-2026)
4.6 Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Oligonucleotide-based Therapy Medicinal Product Market Size by Country (2021-2026)
5.2 Americas Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026)
5.3 Americas Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oligonucleotide-based Therapy Medicinal Product Market Size by Region (2021-2026)
6.2 APAC Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026)
6.3 APAC Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Oligonucleotide-based Therapy Medicinal Product Market Size by Country (2021-2026)
7.2 Europe Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026)
7.3 Europe Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oligonucleotide-based Therapy Medicinal Product by Region (2021-2026)
8.2 Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026)
8.3 Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL OLIGONUCLEOTIDE-BASED THERAPY MEDICINAL PRODUCT MARKET FORECAST
10.1 Global Oligonucleotide-based Therapy Medicinal Product Forecast by Region (2027-2032)
10.1.1 Global Oligonucleotide-based Therapy Medicinal Product Forecast by Region (2027-2032)
10.1.2 Americas Oligonucleotide-based Therapy Medicinal Product Forecast
10.1.3 APAC Oligonucleotide-based Therapy Medicinal Product Forecast
10.1.4 Europe Oligonucleotide-based Therapy Medicinal Product Forecast
10.1.5 Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Forecast
10.2 Americas Oligonucleotide-based Therapy Medicinal Product Forecast by Country (2027-2032)
10.2.1 United States Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.2.2 Canada Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.2.3 Mexico Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.2.4 Brazil Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.3 APAC Oligonucleotide-based Therapy Medicinal Product Forecast by Region (2027-2032)
10.3.1 China Oligonucleotide-based Therapy Medicinal Product Market Forecast
10.3.2 Japan Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.3.3 Korea Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.3.4 Southeast Asia Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.3.5 India Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.3.6 Australia Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.4 Europe Oligonucleotide-based Therapy Medicinal Product Forecast by Country (2027-2032)
10.4.1 Germany Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.4.2 France Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.4.3 UK Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.4.4 Italy Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.4.5 Russia Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.5 Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Forecast by Region (2027-2032)
10.5.1 Egypt Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.5.2 South Africa Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.5.3 Israel Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.5.4 Turkey Market Oligonucleotide-based Therapy Medicinal Product Forecast
10.6 Global Oligonucleotide-based Therapy Medicinal Product Forecast by Type (2027-2032)
10.7 Global Oligonucleotide-based Therapy Medicinal Product Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Oligonucleotide-based Therapy Medicinal Product Forecast
11 KEY PLAYERS ANALYSIS
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Information
11.1.2 Sarepta Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
11.1.3 Sarepta Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Sarepta Therapeutics Main Business Overview
11.1.5 Sarepta Therapeutics Latest Developments
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Information
11.2.2 Ionis Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Product Offered
11.2.3 Ionis Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Ionis Pharmaceuticals Main Business Overview
11.2.5 Ionis Pharmaceuticals Latest Developments
11.3 Alnylam
11.3.1 Alnylam Company Information
11.3.2 Alnylam Oligonucleotide-based Therapy Medicinal Product Product Offered
11.3.3 Alnylam Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Alnylam Main Business Overview
11.3.5 Alnylam Latest Developments
11.4 Biogen
11.4.1 Biogen Company Information
11.4.2 Biogen Oligonucleotide-based Therapy Medicinal Product Product Offered
11.4.3 Biogen Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Biogen Main Business Overview
11.4.5 Biogen Latest Developments
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Information
11.5.2 Nippon Shinyaku Oligonucleotide-based Therapy Medicinal Product Product Offered
11.5.3 Nippon Shinyaku Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Nippon Shinyaku Main Business Overview
11.5.5 Nippon Shinyaku Latest Developments
11.6 Sobi
11.6.1 Sobi Company Information
11.6.2 Sobi Oligonucleotide-based Therapy Medicinal Product Product Offered
11.6.3 Sobi Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sobi Main Business Overview
11.6.5 Sobi Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Oligonucleotide-based Therapy Medicinal Product Product Offered
11.7.3 Novartis Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 BioNTech
11.8.1 BioNTech Company Information
11.8.2 BioNTech Oligonucleotide-based Therapy Medicinal Product Product Offered
11.8.3 BioNTech Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 BioNTech Main Business Overview
11.8.5 BioNTech Latest Developments
11.9 Pfizer
11.9.1 Pfizer Company Information
11.9.2 Pfizer Oligonucleotide-based Therapy Medicinal Product Product Offered
11.9.3 Pfizer Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Pfizer Main Business Overview
11.9.5 Pfizer Latest Developments
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Information
11.10.2 Moderna Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
11.10.3 Moderna Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Moderna Therapeutics Main Business Overview
11.10.5 Moderna Therapeutics Latest Developments
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Information
11.11.2 Jazz Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Product Offered
11.11.3 Jazz Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Jazz Pharmaceuticals Main Business Overview
11.11.5 Jazz Pharmaceuticals Latest Developments
11.12 CureVac
11.12.1 CureVac Company Information
11.12.2 CureVac Oligonucleotide-based Therapy Medicinal Product Product Offered
11.12.3 CureVac Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 CureVac Main Business Overview
11.12.5 CureVac Latest Developments
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Information
11.13.2 Regulus Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
11.13.3 Regulus Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Regulus Therapeutics Main Business Overview
11.13.5 Regulus Therapeutics Latest Developments
11.14 ProQR
11.14.1 ProQR Company Information
11.14.2 ProQR Oligonucleotide-based Therapy Medicinal Product Product Offered
11.14.3 ProQR Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 ProQR Main Business Overview
11.14.5 ProQR Latest Developments
11.15 Secarna
11.15.1 Secarna Company Information
11.15.2 Secarna Oligonucleotide-based Therapy Medicinal Product Product Offered
11.15.3 Secarna Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Secarna Main Business Overview
11.15.5 Secarna Latest Developments
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Information
11.16.2 MiNA Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
11.16.3 MiNA Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 MiNA Therapeutics Main Business Overview
11.16.5 MiNA Therapeutics Latest Developments
11.17 Sylentis
11.17.1 Sylentis Company Information
11.17.2 Sylentis Oligonucleotide-based Therapy Medicinal Product Product Offered
11.17.3 Sylentis Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Sylentis Main Business Overview
11.17.5 Sylentis Latest Developments
11.18 Arrowhead
11.18.1 Arrowhead Company Information
11.18.2 Arrowhead Oligonucleotide-based Therapy Medicinal Product Product Offered
11.18.3 Arrowhead Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Arrowhead Main Business Overview
11.18.5 Arrowhead Latest Developments
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Information
11.19.2 Silence Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
11.19.3 Silence Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Silence Therapeutics Main Business Overview
11.19.5 Silence Therapeutics Latest Developments
11.20 Dicerna
11.20.1 Dicerna Company Information
11.20.2 Dicerna Oligonucleotide-based Therapy Medicinal Product Product Offered
11.20.3 Dicerna Oligonucleotide-based Therapy Medicinal Product Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Dicerna Main Business Overview
11.20.5 Dicerna Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Oligonucleotide-based Therapy Medicinal Product Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Oligonucleotide-based Therapy Medicinal Product Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Antisense Oligonucleotides (ASO)
Table 4. Major Players of siRNA
Table 5. Major Players of mRNA
Table 6. Oligonucleotide-based Therapy Medicinal Product Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Type (2021-2026)
Table 9. Oligonucleotide-based Therapy Medicinal Product Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026) & ($ millions)
Table 11. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Application (2021-2026)
Table 12. Global Oligonucleotide-based Therapy Medicinal Product Revenue by Player (2021-2026) & ($ millions)
Table 13. Global Oligonucleotide-based Therapy Medicinal Product Revenue Market Share by Player (2021-2026)
Table 14. Oligonucleotide-based Therapy Medicinal Product Key Players Head office and Products Offered
Table 15. Oligonucleotide-based Therapy Medicinal Product Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Oligonucleotide-based Therapy Medicinal Product Market Size by Region (2021-2026) & ($ millions)
Table 19. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Region (2021-2026)
Table 20. Global Oligonucleotide-based Therapy Medicinal Product Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global Oligonucleotide-based Therapy Medicinal Product Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas Oligonucleotide-based Therapy Medicinal Product Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Country (2021-2026)
Table 24. Americas Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Type (2021-2026)
Table 26. Americas Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Application (2021-2026)
Table 28. APAC Oligonucleotide-based Therapy Medicinal Product Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Region (2021-2026)
Table 30. APAC Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe Oligonucleotide-based Therapy Medicinal Product Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Country (2021-2026)
Table 34. Europe Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Oligonucleotide-based Therapy Medicinal Product
Table 40. Key Market Challenges & Risks of Oligonucleotide-based Therapy Medicinal Product
Table 41. Key Industry Trends of Oligonucleotide-based Therapy Medicinal Product
Table 42. Global Oligonucleotide-based Therapy Medicinal Product Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global Oligonucleotide-based Therapy Medicinal Product Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global Oligonucleotide-based Therapy Medicinal Product Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. Sarepta Therapeutics Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 47. Sarepta Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 48. Sarepta Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. Sarepta Therapeutics Main Business
Table 50. Sarepta Therapeutics Latest Developments
Table 51. Ionis Pharmaceuticals Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 52. Ionis Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 53. Ionis Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Ionis Pharmaceuticals Main Business
Table 55. Ionis Pharmaceuticals Latest Developments
Table 56. Alnylam Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 57. Alnylam Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 58. Alnylam Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. Alnylam Main Business
Table 60. Alnylam Latest Developments
Table 61. Biogen Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 62. Biogen Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 63. Biogen Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Biogen Main Business
Table 65. Biogen Latest Developments
Table 66. Nippon Shinyaku Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 67. Nippon Shinyaku Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 68. Nippon Shinyaku Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Nippon Shinyaku Main Business
Table 70. Nippon Shinyaku Latest Developments
Table 71. Sobi Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 72. Sobi Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 73. Sobi Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Sobi Main Business
Table 75. Sobi Latest Developments
Table 76. Novartis Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 77. Novartis Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 78. Novartis Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. BioNTech Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 82. BioNTech Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 83. BioNTech Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. BioNTech Main Business
Table 85. BioNTech Latest Developments
Table 86. Pfizer Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 87. Pfizer Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 88. Pfizer Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Moderna Therapeutics Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 92. Moderna Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 93. Moderna Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. Moderna Therapeutics Main Business
Table 95. Moderna Therapeutics Latest Developments
Table 96. Jazz Pharmaceuticals Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 97. Jazz Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 98. Jazz Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. Jazz Pharmaceuticals Main Business
Table 100. Jazz Pharmaceuticals Latest Developments
Table 101. CureVac Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 102. CureVac Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 103. CureVac Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. CureVac Main Business
Table 105. CureVac Latest Developments
Table 106. Regulus Therapeutics Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 107. Regulus Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 108. Regulus Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Regulus Therapeutics Main Business
Table 110. Regulus Therapeutics Latest Developments
Table 111. ProQR Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 112. ProQR Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 113. ProQR Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. ProQR Main Business
Table 115. ProQR Latest Developments
Table 116. Secarna Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 117. Secarna Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 118. Secarna Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Secarna Main Business
Table 120. Secarna Latest Developments
Table 121. MiNA Therapeutics Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 122. MiNA Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 123. MiNA Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. MiNA Therapeutics Main Business
Table 125. MiNA Therapeutics Latest Developments
Table 126. Sylentis Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 127. Sylentis Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 128. Sylentis Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 129. Sylentis Main Business
Table 130. Sylentis Latest Developments
Table 131. Arrowhead Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 132. Arrowhead Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 133. Arrowhead Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 134. Arrowhead Main Business
Table 135. Arrowhead Latest Developments
Table 136. Silence Therapeutics Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 137. Silence Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 138. Silence Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 139. Silence Therapeutics Main Business
Table 140. Silence Therapeutics Latest Developments
Table 141. Dicerna Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 142. Dicerna Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 143. Dicerna Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 144. Dicerna Main Business
Table 145. Dicerna Latest Developments
Table 1. Oligonucleotide-based Therapy Medicinal Product Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Oligonucleotide-based Therapy Medicinal Product Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Antisense Oligonucleotides (ASO)
Table 4. Major Players of siRNA
Table 5. Major Players of mRNA
Table 6. Oligonucleotide-based Therapy Medicinal Product Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Type (2021-2026)
Table 9. Oligonucleotide-based Therapy Medicinal Product Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026) & ($ millions)
Table 11. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Application (2021-2026)
Table 12. Global Oligonucleotide-based Therapy Medicinal Product Revenue by Player (2021-2026) & ($ millions)
Table 13. Global Oligonucleotide-based Therapy Medicinal Product Revenue Market Share by Player (2021-2026)
Table 14. Oligonucleotide-based Therapy Medicinal Product Key Players Head office and Products Offered
Table 15. Oligonucleotide-based Therapy Medicinal Product Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Oligonucleotide-based Therapy Medicinal Product Market Size by Region (2021-2026) & ($ millions)
Table 19. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Region (2021-2026)
Table 20. Global Oligonucleotide-based Therapy Medicinal Product Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global Oligonucleotide-based Therapy Medicinal Product Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas Oligonucleotide-based Therapy Medicinal Product Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Country (2021-2026)
Table 24. Americas Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Type (2021-2026)
Table 26. Americas Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Application (2021-2026)
Table 28. APAC Oligonucleotide-based Therapy Medicinal Product Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Region (2021-2026)
Table 30. APAC Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe Oligonucleotide-based Therapy Medicinal Product Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Country (2021-2026)
Table 34. Europe Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Oligonucleotide-based Therapy Medicinal Product
Table 40. Key Market Challenges & Risks of Oligonucleotide-based Therapy Medicinal Product
Table 41. Key Industry Trends of Oligonucleotide-based Therapy Medicinal Product
Table 42. Global Oligonucleotide-based Therapy Medicinal Product Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global Oligonucleotide-based Therapy Medicinal Product Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global Oligonucleotide-based Therapy Medicinal Product Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. Sarepta Therapeutics Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 47. Sarepta Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 48. Sarepta Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. Sarepta Therapeutics Main Business
Table 50. Sarepta Therapeutics Latest Developments
Table 51. Ionis Pharmaceuticals Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 52. Ionis Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 53. Ionis Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Ionis Pharmaceuticals Main Business
Table 55. Ionis Pharmaceuticals Latest Developments
Table 56. Alnylam Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 57. Alnylam Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 58. Alnylam Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. Alnylam Main Business
Table 60. Alnylam Latest Developments
Table 61. Biogen Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 62. Biogen Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 63. Biogen Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Biogen Main Business
Table 65. Biogen Latest Developments
Table 66. Nippon Shinyaku Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 67. Nippon Shinyaku Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 68. Nippon Shinyaku Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Nippon Shinyaku Main Business
Table 70. Nippon Shinyaku Latest Developments
Table 71. Sobi Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 72. Sobi Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 73. Sobi Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Sobi Main Business
Table 75. Sobi Latest Developments
Table 76. Novartis Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 77. Novartis Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 78. Novartis Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. BioNTech Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 82. BioNTech Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 83. BioNTech Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. BioNTech Main Business
Table 85. BioNTech Latest Developments
Table 86. Pfizer Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 87. Pfizer Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 88. Pfizer Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Moderna Therapeutics Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 92. Moderna Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 93. Moderna Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. Moderna Therapeutics Main Business
Table 95. Moderna Therapeutics Latest Developments
Table 96. Jazz Pharmaceuticals Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 97. Jazz Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 98. Jazz Pharmaceuticals Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. Jazz Pharmaceuticals Main Business
Table 100. Jazz Pharmaceuticals Latest Developments
Table 101. CureVac Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 102. CureVac Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 103. CureVac Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. CureVac Main Business
Table 105. CureVac Latest Developments
Table 106. Regulus Therapeutics Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 107. Regulus Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 108. Regulus Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Regulus Therapeutics Main Business
Table 110. Regulus Therapeutics Latest Developments
Table 111. ProQR Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 112. ProQR Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 113. ProQR Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. ProQR Main Business
Table 115. ProQR Latest Developments
Table 116. Secarna Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 117. Secarna Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 118. Secarna Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Secarna Main Business
Table 120. Secarna Latest Developments
Table 121. MiNA Therapeutics Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 122. MiNA Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 123. MiNA Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. MiNA Therapeutics Main Business
Table 125. MiNA Therapeutics Latest Developments
Table 126. Sylentis Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 127. Sylentis Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 128. Sylentis Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 129. Sylentis Main Business
Table 130. Sylentis Latest Developments
Table 131. Arrowhead Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 132. Arrowhead Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 133. Arrowhead Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 134. Arrowhead Main Business
Table 135. Arrowhead Latest Developments
Table 136. Silence Therapeutics Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 137. Silence Therapeutics Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 138. Silence Therapeutics Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 139. Silence Therapeutics Main Business
Table 140. Silence Therapeutics Latest Developments
Table 141. Dicerna Details, Company Type, Oligonucleotide-based Therapy Medicinal Product Area Served and Its Competitors
Table 142. Dicerna Oligonucleotide-based Therapy Medicinal Product Product Offered
Table 143. Dicerna Oligonucleotide-based Therapy Medicinal Product Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 144. Dicerna Main Business
Table 145. Dicerna Latest Developments
LIST OF FIGURES
Figure 1. Oligonucleotide-based Therapy Medicinal Product Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Oligonucleotide-based Therapy Medicinal Product Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Oligonucleotide-based Therapy Medicinal Product Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Oligonucleotide-based Therapy Medicinal Product Sales Market Share by Country/Region (2025)
Figure 8. Oligonucleotide-based Therapy Medicinal Product Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Type in 2025
Figure 10. Oligonucleotide-based Therapy Medicinal Product in Neuromuscular Diseases
Figure 11. Global Oligonucleotide-based Therapy Medicinal Product Market: Neuromuscular Diseases (2021-2026) & ($ millions)
Figure 12. Oligonucleotide-based Therapy Medicinal Product in hATTR
Figure 13. Global Oligonucleotide-based Therapy Medicinal Product Market: hATTR (2021-2026) & ($ millions)
Figure 14. Oligonucleotide-based Therapy Medicinal Product in COVID-19
Figure 15. Global Oligonucleotide-based Therapy Medicinal Product Market: COVID-19 (2021-2026) & ($ millions)
Figure 16. Oligonucleotide-based Therapy Medicinal Product in Other
Figure 17. Global Oligonucleotide-based Therapy Medicinal Product Market: Other (2021-2026) & ($ millions)
Figure 18. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Application in 2025
Figure 19. Global Oligonucleotide-based Therapy Medicinal Product Revenue Market Share by Player in 2025
Figure 20. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Region (2021-2026)
Figure 21. Americas Oligonucleotide-based Therapy Medicinal Product Market Size 2021-2026 ($ millions)
Figure 22. APAC Oligonucleotide-based Therapy Medicinal Product Market Size 2021-2026 ($ millions)
Figure 23. Europe Oligonucleotide-based Therapy Medicinal Product Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size 2021-2026 ($ millions)
Figure 25. Americas Oligonucleotide-based Therapy Medicinal Product Value Market Share by Country in 2025
Figure 26. United States Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Region in 2025
Figure 31. APAC Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Type (2021-2026)
Figure 32. APAC Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Application (2021-2026)
Figure 33. China Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 37. India Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Country in 2025
Figure 40. Europe Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Type (2021-2026)
Figure 41. Europe Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Application (2021-2026)
Figure 42. Germany Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 43. France Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 56. APAC Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 57. Europe Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 59. United States Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 60. Canada Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 61. Mexico Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 62. Brazil Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 63. China Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 64. Japan Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 65. Korea Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 67. India Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 68. Australia Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 69. Germany Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 70. France Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 71. UK Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 72. Italy Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 73. Russia Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 74. Egypt Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 75. South Africa Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 76. Israel Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 77. Turkey Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 78. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 1. Oligonucleotide-based Therapy Medicinal Product Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Oligonucleotide-based Therapy Medicinal Product Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Oligonucleotide-based Therapy Medicinal Product Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Oligonucleotide-based Therapy Medicinal Product Sales Market Share by Country/Region (2025)
Figure 8. Oligonucleotide-based Therapy Medicinal Product Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Type in 2025
Figure 10. Oligonucleotide-based Therapy Medicinal Product in Neuromuscular Diseases
Figure 11. Global Oligonucleotide-based Therapy Medicinal Product Market: Neuromuscular Diseases (2021-2026) & ($ millions)
Figure 12. Oligonucleotide-based Therapy Medicinal Product in hATTR
Figure 13. Global Oligonucleotide-based Therapy Medicinal Product Market: hATTR (2021-2026) & ($ millions)
Figure 14. Oligonucleotide-based Therapy Medicinal Product in COVID-19
Figure 15. Global Oligonucleotide-based Therapy Medicinal Product Market: COVID-19 (2021-2026) & ($ millions)
Figure 16. Oligonucleotide-based Therapy Medicinal Product in Other
Figure 17. Global Oligonucleotide-based Therapy Medicinal Product Market: Other (2021-2026) & ($ millions)
Figure 18. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Application in 2025
Figure 19. Global Oligonucleotide-based Therapy Medicinal Product Revenue Market Share by Player in 2025
Figure 20. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Region (2021-2026)
Figure 21. Americas Oligonucleotide-based Therapy Medicinal Product Market Size 2021-2026 ($ millions)
Figure 22. APAC Oligonucleotide-based Therapy Medicinal Product Market Size 2021-2026 ($ millions)
Figure 23. Europe Oligonucleotide-based Therapy Medicinal Product Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size 2021-2026 ($ millions)
Figure 25. Americas Oligonucleotide-based Therapy Medicinal Product Value Market Share by Country in 2025
Figure 26. United States Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Region in 2025
Figure 31. APAC Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Type (2021-2026)
Figure 32. APAC Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Application (2021-2026)
Figure 33. China Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 37. India Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Country in 2025
Figure 40. Europe Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Type (2021-2026)
Figure 41. Europe Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Application (2021-2026)
Figure 42. Germany Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 43. France Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Oligonucleotide-based Therapy Medicinal Product Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 56. APAC Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 57. Europe Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 59. United States Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 60. Canada Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 61. Mexico Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 62. Brazil Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 63. China Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 64. Japan Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 65. Korea Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 67. India Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 68. Australia Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 69. Germany Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 70. France Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 71. UK Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 72. Italy Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 73. Russia Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 74. Egypt Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 75. South Africa Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 76. Israel Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 77. Turkey Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
Figure 78. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Oligonucleotide-based Therapy Medicinal Product Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Oligonucleotide-based Therapy Medicinal Product Market Size 2027-2032 ($ millions)
